Arvinas Inc., ARVN, FDA Calendar, PDUFA Date

Company Name	Arvinas, Inc. ARVN
Drug Name	Vepdegestrant (NDA)
Event Name	FDA decision on Vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced breast cancer
Event Date	06/05/2026
Outcome Date	05/01/2026
Outcome	FDA approved vepdegestrant, under the brand name VEPPANU, for the treatment of ESR1m, ER+/HER2- advanced breast cancer on May 1, 2026
Drug Status	Vepdegestrant is being co-developed by Arvinas and Pfizer
Rival Drugs	Menarini's Orserdu, AstraZeneca's Faslodex
Market Potential	If approved Vepdegestrant could achieve peak sales of $2 billion to $4 billion, according to analysts
Other Approvals
News

Return to FDA Calendar

Slide Shows